Concurrent Radiotherapy and Chemotherapy of Vinorelbine and Cisplatin for Locally Advanced Non-small Cell Lung Cancer

ObjectiveTo analysis the toxicities and efficacy of concurrent irradiation and chemotherapy in unresectable locally advanced non-small cell lung cancer (NSCLC). MethodsFrom April 2002 to June 2006, 50 unresectable stage ⅢA(N2) ~ⅢB NSCLC patients received 2 cycles of cisplatin-based chemotherapy with cisplatin（CDDP）30 mg/m2 on day 1～3 and 22~24 and Vinorelbine（VNR）20 mg/m2 on day 1, 8, 22 and 29. Three-dimensional conformal radiotherapy (3DCRT) was administered concurrently in cycle 1 and median radiation dose was 64 Gy. Common terminology criteria for adverse events version 3.0 was used to assess treatment-related adverse events. ResultsThe response rate was 70%. The median survival of disease progression-free and median overall survival(OS) were 7.5 months and 16.1 months, respectively. The 1-, 2- and 3-year survival rates were 60%, 32.7% and 21%, respectively. In the univariaty analysis, clinical stage and dose of radiation were significantly associated with survival and dose of radiation was significantly associated with progression-free survival(PFS). In the multivariate analysis, dose of radiation was significantly associated with OS and PFS. Toxicities were well tolerated. Grade 3 hematologic toxicities consisted mainly of neutropenia (10%). Twenty-six patients presented with grade 1~2 symptomatic radiation pneumonitis. Grade 1~2 acute esophageal toxicity was observed in 20 patients. ConclusionBased on this experience with 50 patients, this concurrent radiotherapy and chemotherapy for inoperable stage Ⅲ NSCLC was feasible with acceptable toxicity.